Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is experiencing a positive outlook due to the continued strong positioning of its lead molecule, cabozantinib, which has shown long-term efficacy data in renal cell carcinoma (RCC) and expanding opportunities in neuroendocrine tumors (NETs) following recent label expansions. The company's development program for zanzalintinib, which has demonstrated statistically significant improvements in overall survival compared to regorafenib, suggests a growing competitive advantage in the metastatic colorectal cancer (mCRC) market. Additionally, the collaboration with Roche for the combination therapy further highlights Exelixis’s strategic potential for future growth in various oncology indications, reinforcing confidence in its prospects.

Bears say

The analysis indicates a significant concern regarding Exelixis, Inc.'s financial outlook due to an anticipated 80% revenue decline following the patent expiration of key products in 2031, which is more severe than the market's expectation of a 68% drop. Additionally, competitive pressures threaten the company’s market share, particularly for its drug cabozantinib in renal cell carcinoma, compounded by uncertainties surrounding unmet market potential in neuroendocrine tumors and hepatocellular carcinoma. Finally, the developmental risks associated with zanzalintinib and the potential for disappointing data updates further exacerbate the concerns regarding Exelixis's future performance.

Exelixis (EXEL) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 19 analysts, Exelixis (EXEL) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.